Pharmafile Logo
Pharmafocus logo
Advanced Search

Alnylam

Showing 14 posts of 14 posts found.

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

July 24, 2023
Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …

News

Alnylam shares positive results from phase 1 trial

July 17, 2023
Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

News
alnylam_credit_-_business_wire

Alnylam’s lumasiran hits main Phase 3 goal in rare renal disease primary hyperoxaluria type 1

June 9, 2020
Manufacturing and Production, Research and Development Alnylam, lumasiran, pharma, rare disease

Alnylam has presented promising new Phase 3 data at the European Renal Association-European Dialysis and Transplant Association International Congress for …

News

NICE recommends Alnylam’s Onpattro for inherited hATTR amyloidosis

July 9, 2019
Manufacturing and Production, Sales and Marketing Alnylam, NHS, Onpattro, UK, hATTR amyloidosis, pharma

It’s good news for UK patients as it emerges that the National Institute of Health and Care Excellence has passed …

News
shutterstock_159488225

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership

April 8, 2019
Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease

Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …

News
handshake

Regeneron-Alnylam team up to treat NASH

March 22, 2018
Research and Development, Sales and Marketing Alnylam, Regeneron, biotech, drugs, nash, pharma, pharmaceutical

Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …

News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …

News

Former Cubist chief executive Michael Bonney to chair board at Alnylam

December 22, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, David Pyott, michael bonney

Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals …

Appointment
genzyme_logo

Genzyme opts into Alnylam’s Thrombosis program

October 2, 2015
Medical Communications, Research and Development Alnylam, Genzyme, Sanofi, haemophilia

Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in …

News
garg_anylynam

Alnylam poaches VP from Bristol-Myers Squibb

November 4, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, pushkal garg

US-based RNAi therapeutics firm Alnylam Pharmaceuticals has appointed Dr Pushkal Garg to the position of senior vice president of its …

Appointment
Sanofi image

Sanofi pays $700m to expand rare disease portfolio

January 13, 2014
Research and Development, Sales and Marketing Alnylam, Sanofi, rare sidease

Sanofi and Alnylam have announced the expansion of their 2012 agreement to develop and sell treatments for rare genetic diseases. …

News
stelios_papadopoulos

Regulus names Stelios Papadopoulos as chairman

June 12, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, Exelixis, Regulas

Biopharma firm Regulas Therapeutics has named Stelios Papadopoulos chairman of its Board of directors.  Papadopoulos assumes the role from John …

Appointment

Alnylam cuts workforce by a third

January 23, 2012
Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai

Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …

News

GSK taps Alnylam tech for vaccine production

November 7, 2011
Manufacturing and Production, Sales and Marketing Alnylam, GSK, vaccines

GlaxoSmithKline has teamed up with gene silencing specialist Alnylam Pharmaceuticals in a project aimed at speeding up the production of …

News

Latest content

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023